変形性関節症の疼痛治療薬市場：薬剤クラス別、投与経路別、流通チャネル別-2025-2030年の世界予測

変形性関節症の疼痛治療薬市場は、2023年に80億3,000万米ドルと評価され、2024年には85億4,000万米ドルに達すると予測され、CAGR 6.47％で成長し、2030年には124億7,000万米ドルに達すると予測されています。

変形性関節症の疼痛治療薬市場には、高齢者に多い退行性関節疾患である変形性関節症に伴う痛みを緩和するために開発された医薬品が含まれます。この市場には、非ステロイド性抗炎症薬（NSAIDs）、鎮痛薬、COX-2阻害薬、コルチコステロイドなど、さまざまな種類の薬剤が含まれます。これらの薬剤の需要を牽引しているのは、世界人口の高齢化、肥満率の増加、関節変性のリスクを高めるライフスタイルの変化による変形性関節症の有病率の増加です。変形性関節症の疼痛治療薬の必要性は、慢性的でしばしば衰弱し、生活の質に重大な影響を及ぼすこの疾患の性質によって強調されています。これらの薬剤の用途は、痛みを和らげるだけでなく、可動性や全体的な機能の改善にも及ぶため、その開発はヘルスケアにとって極めて重要です。最終用途には主に病院、診療所、在宅介護の現場が含まれます。主な成長要因としては、ドラッグデリバリーシステムの発展や、副作用を最小限に抑えた効果的な治療法の研究開発への投資の増加が挙げられます。個別化医療や生物学的製剤の台頭は、ヘルスケアのインフラが改善しつつある新興市場への進出と同様に、潜在的なビジネスチャンスをもたらしています。しかし課題としては、規制当局の厳しい承認、これらの医薬品の長期使用による副作用の可能性、理学療法や栄養補助食品などの代替療法との競合などが挙げられます。さらに、高額な薬剤費と償還の問題は、アクセシビリティと市場拡大を制限する可能性があります。事業成長のためには、新規作用機序、安全性プロファイルの改善、有効性の向上を備えた医薬品の開発にイノベーションを集中させる必要があります。また、バイオマーカーを探索することで、よりオーダーメイドの治療アプローチが可能になり、競争力を高めることができます。市場の競争は激しく、大手企業は市場シェアの維持・拡大のために研究開発に多額の投資を行っています。全体として、市場情勢は大きな成長の可能性を秘めているが、規制状況や競合情勢を戦略的にナビゲートする必要があります。

市場力学：急速に進化する変形性関節症の疼痛治療薬市場の主要市場インサイトを公開

変形性関節症の疼痛治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 変形性関節症の有病率の増加と変形性関節症に罹患しやすい人口の増加
  • スポーツ障害の増加
  • 消費者の意識レベルの向上と技術の改善
• 市場抑制要因
  • 薬剤開発の高コストと深刻な副作用
• 市場機会
  • ヘルスケアと医薬品分野の進歩
  • 継続的な研究開発
  • 医薬品供給のための政府と非公開会社の提携
• 市場の課題
  • 偽造医薬品や安価な医薬品の存在

ポーターの5つの力：変形性関節症の疼痛治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：変形性関節症の疼痛治療薬市場における外部からの影響の把握

外部マクロ環境要因は、変形性関節症の疼痛治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析変形性関節症の疼痛治療薬市場における競合情勢の把握

変形性関節症の疼痛治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス変形性関節症の疼痛治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、変形性関節症の疼痛治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨変形性関節症の疼痛治療薬市場における成功への道筋を描く

変形性関節症の疼痛治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 変形性関節症の罹患率の増加と変形性関節症にかかりやすい人口の増加
    • スポーツ傷害の増加
    • 消費者の意識レベルの向上と技術の向上
  • 抑制要因
    • 医薬品開発の高コストと重篤な副作用
  • 機会
    • ヘルスケアと製薬分野の進歩
    • 進行中の研究開発
    • 医薬品供給における政府と非公開会社の協力
  • 課題
    • 偽造医薬品や安価な医薬品の存在
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 変形性関節症の疼痛治療薬市場薬剤クラス別

• コルチコステロイド
• NSAIDs
• 関節内補充療法

第7章 変形性関節症の疼痛治療薬市場：投与経路別

• オーラル
• 非経口
• 話題

第8章 変形性関節症の疼痛治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの変形性関節症の疼痛治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の変形性関節症の疼痛治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの変形性関節症の疼痛治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Abiogen Pharma Spa
• Bayer AG
• Bioventus
• Eli Lilly and Company
• Ferring B.V.
• GlaxoSmithKline Plc.
• Horizon Therapeutics plc
• Johnson & Johnson Private Limited
• Medivir AB
• Merck Sharp & Dohme Corp.
• Novartis AG
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. OSTEOARTHRITIS PAIN DRUG MARKET RESEARCH PROCESS
• FIGURE 2. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OSTEOARTHRITIS PAIN DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OSTEOARTHRITIS PAIN DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTERIODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Osteoarthritis Pain Drug Market was valued at USD 8.03 billion in 2023, expected to reach USD 8.54 billion in 2024, and is projected to grow at a CAGR of 6.47%, to USD 12.47 billion by 2030.

The osteoarthritis pain drug market encompasses medications developed to alleviate pain associated with osteoarthritis, a degenerative joint disease commonly affecting the elderly. This market includes various drug types such as NSAIDs, analgesics, COX-2 inhibitors, and corticosteroids. The demand for these drugs is driven by the growing prevalence of osteoarthritis due to an aging global population, increasing obesity rates, and lifestyle changes that heighten the risk of joint degeneration. The necessity for osteoarthritis pain medication is underscored by the chronic and often debilitating nature of the condition, which significantly impacts the quality of life. Applications of these drugs extend beyond pain relief to improving mobility and overall function, making their development crucial for healthcare. End-use scope primarily includes hospitals, clinics, and home care settings. Key growth factors include advances in drug delivery systems and increased investment in research and development for effective therapies with minimal side effects. The rise of personalized medicine and biologic drugs presents potential opportunities, as does the expansion into emerging markets where healthcare infrastructure is improving. However, challenges include stringent regulatory approvals, potential side effects of long-term use of these drugs, and competition from alternative therapies like physical therapy and dietary supplements. Moreover, high drug costs and reimbursement issues can limit accessibility and market expansion. For business growth, innovation should focus on developing drugs with novel mechanisms of action, improved safety profiles, and enhanced efficacy. Exploring biomarkers for more tailored treatment approaches could also provide a competitive edge. The market is characterized by high competition, with major players investing heavily in R&D to maintain or augment their market share. Overall, the osteoarthritis pain drug market offers significant growth potential but requires strategic navigation of regulatory and competitive landscapes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoarthritis Pain Drug Market

The Osteoarthritis Pain Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of osteoarthritis and growing population susceptible to osteoarthritis
  • Rising number of sports injuries
  • Increasing consumer awareness level and improved technology
• Market Restraints
  • High cost of drug development and severe side-effects
• Market Opportunities
  • Advancement in the healthcare and pharmaceutical sectors
  • Ongoing research and development
  • Collaborations between governments and private companies for the supply of drugs
• Market Challenges
  • Presence of counterfeit and cheap quality drugs

Porter's Five Forces: A Strategic Tool for Navigating the Osteoarthritis Pain Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoarthritis Pain Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoarthritis Pain Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoarthritis Pain Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoarthritis Pain Drug Market

A detailed market share analysis in the Osteoarthritis Pain Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoarthritis Pain Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoarthritis Pain Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoarthritis Pain Drug Market

A strategic analysis of the Osteoarthritis Pain Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoarthritis Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abiogen Pharma Spa, Bayer AG, Bioventus, Eli Lilly and Company, Ferring B.V., GlaxoSmithKline Plc., Horizon Therapeutics plc, Johnson & Johnson Private Limited, Medivir AB, Merck Sharp & Dohme Corp., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Osteoarthritis Pain Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Corticosteriods, NSAIDs, and Viscosupplementation.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of osteoarthritis and growing population susceptible to osteoarthritis
    • 5.1.1.2. Rising number of sports injuries
    • 5.1.1.3. Increasing consumer awareness level and improved technology
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of drug development and severe side-effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
    • 5.1.3.2. Ongoing research and development
    • 5.1.3.3. Collaborations between governments and private companies for the supply of drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Presence of counterfeit and cheap quality drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Osteoarthritis Pain Drug Market, by Drug Class

• 6.1. Introduction
• 6.2. Corticosteriods
• 6.3. NSAIDs
• 6.4. Viscosupplementation

7. Osteoarthritis Pain Drug Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral
• 7.4. Topical

8. Osteoarthritis Pain Drug Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Osteoarthritis Pain Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Osteoarthritis Pain Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Osteoarthritis Pain Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Abiogen Pharma Spa
• 3. Bayer AG
• 4. Bioventus
• 5. Eli Lilly and Company
• 6. Ferring B.V.
• 7. GlaxoSmithKline Plc.
• 8. Horizon Therapeutics plc
• 9. Johnson & Johnson Private Limited
• 10. Medivir AB
• 11. Merck Sharp & Dohme Corp.
• 12. Novartis AG
• 13. Pfizer, Inc.
• 14. Regeneron Pharmaceuticals, Inc.
• 15. Sanofi S.A.